
Release date: 2026-04-09 13:31:16 Article From: Lucius Laos Recommended: 19
It is not known whether larotrectinib has an effect on the unborn baby; therefore, this product should not be used during pregnancy. If you are pregnant, suspect you may be pregnant, or plan to become pregnant, you must consult a doctor before taking this medicine. Similarly, as it is unknown whether larotrectinib is excreted in breast milk, you must not breastfeed during treatment and for 3 days after the last dose to ensure the safety of the infant.
Women of childbearing potential and men who have sexual intercourse with women of childbearing potential must use effective contraceptive measures during treatment and for at least one month after the last dose. If hormonal contraceptives (e.g., birth control pills) are used, an additional barrier contraceptive method (e.g., condoms) must be employed.
For adults aged 18 years and above, the recommended dose of larotrectinib is 100 mg twice daily. The 100 mg dose may be taken as one 100 mg capsule or four 25 mg capsules. Your doctor will assess whether dose adjustment is needed based on your physical condition and treatment response.
For children and adolescents, the doctor will calculate an accurate individualized dose according to the child’s specific height and weight. The maximum recommended dose for children is also 100 mg twice daily. An oral solution formulation is available for patients who cannot swallow hard capsules. You must strictly take the medicine as directed by your doctor.
Larotrectinib may be taken with or without food, but the capsules must be swallowed whole with a full glass of water. Do not open, chew, or crush the capsules, as their contents have an extremely bitter taste.
If you forget to take a dose or vomit after taking the medicine, do not take a double dose to make up for the missed one. Simply take the next dose at the usual scheduled time.
If you suspect an overdose, contact a doctor, pharmacist, or go to the nearest hospital emergency department immediately, and bring the medicine packaging and instructions with you. Do not stop taking the medicine without first consulting your doctor.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2292025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4562024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2382025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2282025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:2612025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2382025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2222025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: